Cell-Penetrating Peptide Nanocarriers: Molecular Trojans for Glioblastoma Drug Delivery
Nano-biohybrids combining nanocarriers with cell-penetrating peptides offer a promising strategy to cross the blood-brain barrier and deliver drugs to glioblastoma tumors.
Quick Facts
What This Study Found
Nano-biohybrids combining nanocarriers with cell-penetrating peptides show promise for crossing the BBB and delivering therapeutics to glioblastoma tumor cells.
Key Numbers
Reviews CPP types, nanocarrier designs, BBB and BTB penetration mechanisms, and strategies to overcome instability, degradation, and immunogenicity.
How They Did This
Review of nanocarrier-CPP hybrid systems for glioblastoma drug delivery, covering design strategies, BBB penetration mechanisms, and preclinical evidence.
Why This Research Matters
Glioblastoma has virtually no effective treatments largely because drugs cannot reach the tumor through the BBB. Cell-penetrating peptide nanocarriers could solve this fundamental delivery problem.
The Bigger Picture
If CPP-nanocarrier technology can crack the BBB problem, it could transform not just brain cancer treatment but therapy for any neurological condition requiring drug delivery to the brain.
What This Study Doesn't Tell Us
Most evidence is preclinical. CPP-nanocarriers face challenges including rapid systemic clearance, potential off-target accumulation, and manufacturing complexity.
Questions This Raises
- ?Which CPP sequences provide the best BBB penetration with minimal off-target effects?
- ?Can these nanocarriers achieve sufficient drug concentrations in glioblastoma tumors for meaningful clinical benefit?
Trust & Context
- Key Stat:
- Molecular Trojan horses Cell-penetrating peptide nanocarriers can slip past the blood-brain barrier to deliver drugs directly to glioblastoma tumor cells
- Evidence Grade:
- Review of preclinical research — summarizes a promising but still early-stage technology. Clinical translation remains years away.
- Study Age:
- Published in 2025, reviewing the latest advances in CPP-nanocarrier systems for brain tumor drug delivery.
- Original Title:
- Nano-biohybrids with cell-penetrating peptides: A molecular trojans for glioblastoma precision medicine.
- Published In:
- International journal of pharmaceutics, 683, 126077 (2025)
- Authors:
- Phatale, Vivek, Khairnar, Pooja, Shukla, Shalini, Puri, Niharika, Sahane, Prajakta, Srivastava, Saurabh
- Database ID:
- RPEP-13044
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Why is glioblastoma so hard to treat?
The blood-brain barrier blocks most drugs from reaching the brain, and glioblastoma cells are aggressive and resistant to treatment. Even when surgery removes visible tumor, cancer cells infiltrate surrounding brain tissue, making complete treatment extremely difficult.
How do cell-penetrating peptides help?
Cell-penetrating peptides are short protein sequences that can cross cell membranes and the blood-brain barrier. When attached to drug-carrying nanoparticles, they act as delivery vehicles — molecular Trojan horses — that ferry medications past the brain's natural defenses and directly into tumor cells.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13044APA
Phatale, Vivek; Khairnar, Pooja; Shukla, Shalini; Puri, Niharika; Sahane, Prajakta; Srivastava, Saurabh. (2025). Nano-biohybrids with cell-penetrating peptides: A molecular trojans for glioblastoma precision medicine.. International journal of pharmaceutics, 683, 126077. https://doi.org/10.1016/j.ijpharm.2025.126077
MLA
Phatale, Vivek, et al. "Nano-biohybrids with cell-penetrating peptides: A molecular trojans for glioblastoma precision medicine.." International journal of pharmaceutics, 2025. https://doi.org/10.1016/j.ijpharm.2025.126077
RethinkPeptides
RethinkPeptides Research Database. "Nano-biohybrids with cell-penetrating peptides: A molecular ..." RPEP-13044. Retrieved from https://rethinkpeptides.com/research/phatale-2025-nanobiohybrids-with-cellpenetrating-peptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.